Recent developments include leadership changes, clinical trial progress, and financial results reflecting ongoing development and operational challenges.

• Keros appointed Anne Prener to its Board of Directors in June 2026 [N2].
• The company reported a wider than expected Q1 2026 loss with revenues plunging year over year [N3].
• Keros Therapeutics reported Q1 2026 loss and missed revenue estimates [N4].
• The Phase 3 RENEW clinical trial for elritercept in MDS patients progressed with milestone payments from Takeda [S3].

Keros Therapeutics leverages deep scientific expertise in TGF-β signaling to develop novel therapeutics addressing significant unmet needs in neuromuscular and hematologic diseases. Its lead candidate, rinvatercept, has demonstrated promising Phase 1 safety and pharmacodynamic data, supporting advancement into Phase 2 trials. Strategic licensing agreements with Takeda and Hansoh provide substantial upfront and milestone payments, supporting development and potential commercialization. The company’s strong cash position and high liquidity ratios provide financial flexibility to advance its pipeline.

Keros Therapeutics faces risks typical of clinical-stage biopharmaceutical companies, including the uncertainty of clinical trial results and regulatory approvals for its product candidates. The company reported no revenue and sustained net losses, reflecting ongoing development costs without current commercial products. Dependence on partners Takeda and Hansoh for commercialization of elritercept introduces execution risk. Manufacturing and regulatory compliance challenges with third-party suppliers could disrupt development and commercialization. Market competition and the complexity of targeting TGF-β pathways also present challenges.

Keros Therapeutics’ moat is based on its proprietary understanding and targeting of the TGF-β family of proteins, which are master regulators of multiple tissue types. Its focused pipeline on neuromuscular and hematologic diseases with limited current treatment options, combined with strategic partnerships with Takeda and Hansoh for commercialization, provides a competitive position. The company’s advanced clinical programs and exclusive licenses on key patents further support its differentiation. However, as a clinical-stage biopharmaceutical company, it faces typical industry risks including clinical trial outcomes, regulatory approvals, and reliance on partners for commercialization.

• Clinical Development Risk: The success of Keros’ product candidates depends on positive clinical trial outcomes and regulatory approvals, which are inherently uncertain.
• Commercialization Risk: The company relies on partners Takeda and Hansoh for commercialization of elritercept, and their performance impacts potential revenue.
• Financial Risk: Keros has no current product revenue and reports net losses, requiring continued financing to support operations and development.
• Manufacturing Risk: Dependence on third-party manufacturers without alternative production plans could cause supply disruptions.
• Regulatory Risk: Compliance with regulatory requirements is critical; failure could result in enforcement actions and delays.

• Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics targeting dysfunctional signaling of the transforming growth factor-beta (TGF-β) family of proteins, which regulate growth, repair, and maintenance of tissues including skeletal muscle, bone, adipose, heart tissue, and blood [S1].
• The company’s lead product candidate is rinvatercept (KER-065), designed to inhibit TGF-β ligands such as myostatin and activin A, negative regulators of muscle and bone mass, aiming to increase muscle regeneration, size, strength, reduce fat and fibrosis, and improve bone strength. It is being developed for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS) [S1].
• Rinvatercept completed a Phase 1 clinical trial in healthy adult volunteers with topline results announced in March 2025, showing safety and pharmacodynamic effects including increased lean muscle mass, bone mineral density, and reduced fat mass [S1].
• A Phase 2 clinical trial for rinvatercept in DMD patients was planned to commence in Q2 2026, focusing on safety, tolerability, pharmacokinetics, and functional improvements. Regulatory engagement for a Phase 2 trial in ALS patients was planned for the second half of 2026 [S1].
• The company’s most advanced product candidate is elritercept (KER-050), an engineered ligand trap targeting TGF-β signaling to increase red blood cell and platelet production, being developed for myelodysplastic syndromes (MDS) and myelofibrosis [S1].
• Keros entered an exclusive license agreement with Takeda Pharmaceuticals effective January 16, 2025, granting Takeda rights to develop, manufacture, and commercialize elritercept outside mainland China, Hong Kong, and Macau. Keros received a $200 million upfront payment and milestone payments including $10 million upon dosing the first patient in the Phase 3 RENEW trial in July 2025 [S1, S3].
• The company also has a license agreement with Hansoh for elritercept in mainland China, Hong Kong, and Macau, with upfront payments and milestone payments disclosed [S4].
• Keros reported no revenue and a net loss of $28.7 million for the quarter ended June 30, 2026, with basic and diluted EPS of -$1.45. Cash and cash equivalents were $257.6 million, current assets $266.9 million, current liabilities $12.2 million, resulting in a strong current ratio of 21.96 and cash ratio of 21.2 as of June 30, 2026 [S2].
• The company’s strategy includes advancing clinical development of rinvatercept, pursuing commercialization independently or via collaborations, expanding its proprietary molecule library targeting TGF-β pathways, and maintaining a data-driven operating model [S1].
• Duchenne muscular dystrophy is a progressive neuromuscular disease characterized by muscle degeneration, loss of ambulation, and early mortality. Current treatments include glucocorticoids and exon-skipping therapies with limitations and side effects [S1].
• Amyotrophic lateral sclerosis is a fatal neurodegenerative disease with limited treatment options offering modest clinical efficacy. Rinvatercept aims to preserve muscle strength by maximizing function of healthy muscle fibers [S1].
• Recent news includes appointment of Anne Prener to the board of directors in June 2026, and milestone payments related to elritercept development with Takeda [N2].
• Recent quarterly results showed wider than expected losses and revenue declines year over year for Q1 2026 [N3, N4].